Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGERS: Transcriptomic effects of TNF and IL-23 blockade in psoriatic arthritis synovium
2017-003249-18Phase 2Completed
- Sponsor
- Cliniques universitaires Saint-Luc
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ustekinumab, guselkumab, adalimumab in psoriatic arthritis (PsA), sponsored by Cliniques universitaires Saint-Luc. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2017-003249-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003249-18.